This is a multi-centre non-interventional study of patients who are treated with any HMGCoA reductase inhibitor available in Croatia (rosuvastatin, simvastatin, atorvastatin and fluvastatin) for at least 6 months. All HMG-CoA reductase inhibitors must be prescribed in accordance with SmPCs approved in Croatia. Data collection for each patient will take place at a single visit. The investigator will complete a Case Report Form with the patient's demographics, the presence of the factors for high cardiovascular risk, current treatment, cholesterol values as well as with further treatment decision.
Study Type
OBSERVATIONAL
Enrollment
1,868
Research Site
Biograd na Moru, Croatia
Research Site
Bjelovar, Croatia
Research Site
Crikvenica, Croatia
Research Site
Čakovec, Croatia
Research Site
Dubrovnik, Croatia
Research Site
Gospić, Croatia
Research Site
Karlovac, Croatia
Research Site
Koprivnica, Croatia
Research Site
Krapina, Croatia
Research Site
Krapinske Toplice, Croatia
...and 17 more locations
Number of patients reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline
Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated
Percentage of patients reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline
Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated
Number of patients reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline.
Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated
Number of patients with high cardiovascular risk reaching the LDL-C goals according to the Fourth Joint European Task Force guideline.
Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated
Number of patients with high cardiovascular risk reaching the total cholesterol goals according to the Fourth Joint European Task Force guideline.
Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated
Percentage of patients reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline.
Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated
Percentage of patients with high cardiovascular risk reaching the LDL-C goals according to the Fourth Joint European Task Force guideline.
Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated
Percentage of patients with high cardiovascular risk reaching the total cholesterol goals according to the Fourth Joint European Task Force guideline.
Time frame: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.